Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing

Jun 02, 2020•over 5 years ago

Amount Raised

$3 Million

Round Type

series a

Description

Re-Vana Therapeutics Ltd, a privately-held specialty therapeutic and drug delivery company developing sustained-release therapeutics for significant sight-threatening ocular diseases, today announced that it has closed $3.25 million in pre-series A financing. The pre-series A round was oversubscribed by more than $1 million and closed in two tranches. The first tranche of $2.08 million was led by ExSight Ventures, with participation from InFocus Capital Partners and existing U.K. investors, including TechStart Ventures, Clarendon Fund Managers and Qubis Ltd

Company Information

Company

About

AccelFoods is an early-stage venture fund investing in consumer products. We partner with entrepreneurs to bring innovative, high-quality food and beverage products to the forefront of the industry and create the next generation of enduring brands. With nearly $40m under management, we are hands-on partners that work tactically with our founders to scale their businesses quickly and smartly. We connect the dots within the broader food & beverage ecosystem to provide unique access, share distinct expertise, and build solid infrastructure.

Related People

1 contact

Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information